Understanding Growth Factors in Wound Healing

Growth factors are endogenous signaling proteins that regulate key cellular events such as proliferation, migration, differentiation, and angiogenesis. In normal wound healing, these molecules are secreted by platelets, macrophages, fibroblasts, and other cells in a tightly orchestrated sequence. However, chronic wounds often exhibit a deficiency or dysregulation of growth factors, leading to stalled healing. Delivering exogenous growth factors directly to the wound site can restore the molecular environment needed for progression through the inflammatory, proliferative, and remodeling phases. The therapeutic potential of this approach has driven extensive research into biomaterial-based delivery systems that protect these fragile proteins and release them in a controlled manner.

Mechanism of Action

Growth factors bind to specific cell surface receptors, triggering intracellular signaling cascades. For example, platelet-derived growth factor (PDGF) binds to PDGF receptors on fibroblasts and smooth muscle cells, promoting chemotaxis and mitogenesis. Vascular endothelial growth factor (VEGF) acts on endothelial cells to stimulate new blood vessel formation, improving oxygen and nutrient delivery. Transforming growth factor-beta (TGF-β) regulates extracellular matrix synthesis and immune modulation. Basic fibroblast growth factor (bFGF) enhances granulation tissue formation and epithelialization. The combined effect is a coordinated acceleration of wound closure and tissue remodeling. Each growth factor activates distinct downstream pathways—such as MAPK, PI3K/Akt, and Smad signaling—that control gene expression for proliferation, migration, and matrix deposition. Understanding these pathways has enabled the rational design of combination therapies that target multiple phases of healing simultaneously.

Beyond individual factors, the temporal sequence of growth factor activity matters. In acute wounds, PDGF and VEGF appear early to recruit cells and build blood vessels, while TGF-β peaks later to organize collagen and reduce scarring. Chronic wounds often have an imbalance in this sequence. Exogenous growth factor dressings aim to re-establish the correct timing and concentration gradients. For instance, a dressing that releases PDGF during the first few days followed by VEGF and bFGF can mimic the natural cascade more closely than a single bolus. This synchronized delivery approach is a key area of innovation in dressing design.

Key Growth Factors Used in Dressings

  • Platelet-derived growth factor (PDGF): Promotes fibroblast proliferation and angiogenesis. Used clinically in recombinant form (becaplermin) for diabetic foot ulcers. PDGF also induces the expression of other growth factors, amplifying its effect.
  • Vascular endothelial growth factor (VEGF): Stimulates endothelial cell migration and capillary formation, critical for granulation tissue. VEGF isoforms differ in receptor affinity and tissue distribution; VEGF‑A is the most studied in wound healing.
  • Transforming growth factor-beta (TGF-β): Modulates inflammation, stimulates collagen synthesis, and regulates scar formation. TGF-β3 is associated with reduced scarring, while TGF-β1 and β2 can promote fibrosis if overexpressed.
  • Basic fibroblast growth factor (bFGF): Enhances fibroblast and keratinocyte activity, supports granulation and re-epithelialization. bFGF also promotes angiogenesis and is particularly effective in burn wounds.
  • Epidermal growth factor (EGF): Promotes keratinocyte proliferation and migration, directly accelerating epithelial closure. EGF is often used in combination with other growth factors for full-thickness wounds.
  • Insulin-like growth factor 1 (IGF-1): Works synergistically with PDGF and EGF to stimulate cell survival and matrix synthesis. Some dressings now incorporate IGF-1 to support healing in diabetic wounds.

Each growth factor has a specific role, and combinations may offer synergistic benefits. For instance, PDGF and VEGF together can enhance both cell recruitment and vascularization, while TGF-β helps organize the newly formed matrix. A 2021 review in International Journal of Molecular Sciences provides a comprehensive overview of growth factor signaling in wound healing and highlights the potential of dual‑release systems.

Types of Innovative Dressings with Growth Factors

Modern dressings incorporate growth factors using various biomaterial platforms. The choice of carrier affects release kinetics, stability, and biocompatibility. Here are the most common types, each with distinct advantages for specific wound types and healing phases.

Hydrogel Dressings

Hydrogels are three-dimensional polymer networks with high water content, providing a moist environment that facilitates growth factor solubility and diffusion. Growth factors can be loaded directly into the hydrogel matrix or encapsulated in microspheres for sustained release. These dressings are ideal for partial-thickness wounds, burns, and chronic ulcers. They maintain hydration, allow gas exchange, and can be designed to be biodegradable or removable. Recent innovations include thermoresponsive hydrogels that gel in situ, conforming to irregular wound shapes, and injectable hydrogels that fill deep cavity wounds. Hyaluronic acid‑based hydrogels, for example, can simultaneously deliver growth factors and provide a scaffold for cell migration. Some hydrogels are engineered with cleavable crosslinks that release growth factors in response to matrix metalloproteinase activity, which is elevated in chronic wounds, enabling on‑demand delivery.

Collagen-Based Dressings

Collagen is a natural component of the extracellular matrix, making it one of the most biocompatible carriers. Collagen dressings can be formulated as sponges, sheets, or gels. Growth factors are often cross-linked or absorbed into the collagen matrix. When applied, collagen provides a scaffold for cell infiltration while releasing growth factors in a controlled manner. Collagen dressings also attract endogenous fibroblasts and support deposition of new matrix. They are particularly useful for deep chronic wounds with significant tissue loss. Type I collagen is most common, but type III collagen and gelatin (denatured collagen) are also used. Combining collagen with elastin or hyaluronic acid can enhance mechanical properties and angiogenic potential. Clinical studies have shown that collagen sponges loaded with bFGF or PDGF can accelerate granulation tissue formation in pressure ulcers and surgical wounds.

Biodegradable Scaffolds

These dressings are fabricated from synthetic or natural biodegradable polymers (e.g., polylactic-co-glycolic acid [PLGA], chitosan, alginate, silk fibroin) and are designed to gradually degrade as the wound heals. Growth factors are embedded within the scaffold and released as the polymer breaks down. The degradation rate can be tuned to match the healing timeline by adjusting polymer molecular weight or copolymer ratio. Scaffolds can also be loaded with multiple growth factors at different depths to create a sequential release profile—mimicking the natural cascade of healing signals. For example, PLGA microspheres containing PDGF and VEGF have been embedded in a chitosan scaffold to achieve a two‑stage release: first PDGF to recruit fibroblasts, then VEGF to stimulate angiogenesis. This approach has shown superior closure rates in preclinical diabetic wound models compared to simultaneous release.

Nanoparticle-Based Delivery Systems

Nanoparticles protect growth factors from enzymatic degradation and allow targeted delivery to specific cell types. Common materials include lipid nanoparticles (e.g., liposomes, solid lipid nanoparticles), polymeric nanoparticles (e.g., PLGA, poly‑ε‑caprolactone), and mesoporous silica nanoparticles. Nanoparticles can be incorporated into a dressing matrix or applied topically as a spray or gel. They enable precise dosing and prolonged release, reducing the frequency of dressing changes. Surface modification with ligands (e.g., antibodies to CD44 for targeting macrophages) can further improve specificity. A 2020 study in Biomaterials demonstrated that nanoparticle-encapsulated VEGF and PDGF significantly improved wound closure in a diabetic mouse model compared to free growth factors—attributed to sustained release and protection from proteases. Lipid‑based nanoparticles are particularly attractive because they can encapsulate both hydrophilic and hydrophobic agents and are already used in other drug delivery applications.

Electrospun Nanofiber Dressings

Electrospinning produces ultrafine fibers that mimic the fibrous structure of the extracellular matrix. Growth factors can be blended into the polymer solution before spinning or immobilized onto fiber surfaces using covalent bonding or layer‑by‑layer assembly. The high surface area and porosity of nanofiber mats enhance cell adhesion and growth factor bioavailability. These dressings are lightweight, conformable, and can be loaded with multiple bioactive agents. Core‑shell fibers allow encapsulation of growth factors in the core for sustained release while the shell provides structural integrity. Electrospun dressings have been tested in both acute and chronic wound applications, with results showing accelerated re‑epithelialization and reduced scar formation in animal models. Polycaprolactone and gelatin blends are popular because they combine synthetic strength with natural biocompatibility.

Foam and Silicone Dressings

While less common than hydrogels or collagen, some foam dressings are being modified to incorporate growth factors. Polyurethane foams provide excellent exudate management and a moist environment. Growth factors can be loaded into the foam matrix or into absorbent layers. Silicone dressings with a wound‑contact layer coated with growth factors are also being developed; these are non‑adherent and can be changed with minimal trauma. Although foam and silicone carriers currently represent a smaller portion of the research pipeline, their clinical familiarity and ease of use make them promising formats for commercialization once stability challenges are addressed.

Clinical Applications and Evidence

Chronic Wounds

Chronic wounds, including diabetic foot ulcers, pressure ulcers, and venous leg ulcers, are the primary targets for growth factor dressings. These wounds often have impaired angiogenesis, persistent inflammation, and low levels of endogenous growth factors. The goal of these dressings is to restart the stalled healing process by providing the missing biochemical signals in a sustained and localized manner.

Numerous clinical trials have evaluated growth factor–loaded dressings. For example, a recent meta-analysis of 12 randomized controlled trials found that dressings containing PDGF, bFGF, or EGF significantly reduced the time to complete wound closure in diabetic foot ulcers compared to standard care—by an average of 4 to 6 weeks in many studies. Another study on VEGF-releasing scaffolds showed improved granulation tissue formation in pressure ulcers, with a higher proportion of wounds achieving 50% reduction in area by week 4. A 2022 systematic review in Advances in Wound Care concluded that growth factor dressings are most effective when combined with debridement, infection control, and offloading. The review also emphasized that the quality of evidence is strongest for PDGF and bFGF, with more heterogeneous results for EGF and VEGF.

Real‑world evidence is also accumulating. A large retrospective cohort study of over 2,000 patients with diabetic foot ulcers found that those treated with a collagen‑PDGF dressing had a significantly lower amputation rate (12% vs. 21%) and faster healing times compared to patients receiving conventional dressings. These findings support the translation of growth factor dressings from controlled trials into routine clinical practice, though cost remains a barrier in many healthcare systems.

Acute Wounds and Burns

In acute wounds, such as surgical incisions and burns, growth factor dressings can accelerate epithelialization and reduce hypertrophic scarring. Animal models have shown that bFGF-releasing dressings promote rapid closure of full-thickness burns and improve dermal regeneration, with less contraction and better cosmetic outcomes. Clinical data, though still limited, suggest benefits for split-thickness skin graft donor sites and second-degree burns. EGF-loaded hydrogels have been used to enhance re-epithelialization in superficial wounds, reducing healing time by 2–3 days in controlled trials. For surgical wounds, a randomized prospective study found that a PDGF‑loaded collagen sponge applied to median sternotomy incisions reduced the incidence of delayed healing and infection in high‑risk diabetic patients.

Growth factor dressings are also being explored for wound healing in special populations, such as patients on corticosteroids or with radiation‑induced skin damage, where endogenous growth factor levels are suppressed. Early results are encouraging, but larger trials with standardized endpoints are needed to establish clear indications.

Product Examples

One of the few commercially available growth factor products is becaplermin gel (Regranex), a recombinant PDGF-BB gel approved for diabetic foot ulcers. While not a dressing per se, it is applied topically. Newer dressing‑based products include collagen sponges with embedded growth factors by companies such as Integra LifeSciences and AxoGen, as well as nanoparticle‑infused bandages being developed by start‑ups like Celularity and Kuros Biosciences. Some products combine growth factors with antiseptic agents like silver or polyhexanide, aiming to address both infection and healing. The field is moving toward commercializing dressing formats that are easier for clinicians to use and improve patient compliance—for instance, single‑use freeze‑dried wafers that are rehydrated at the bedside. Regulatory approvals outside the U.S., such as India’s DCGI approval of a bFGF‑loaded hydrogel for burn wounds, indicate growing global acceptance.

Advantages and Limitations

Advantages

  • Accelerated wound closure: Growth factors directly stimulate cell proliferation and migration, reducing healing time by days to weeks. In chronic wounds, this can lower the risk of amputation and hospital readmission.
  • Reduced infection risk: Faster closure means shorter exposure to potential pathogens. Some dressings also incorporate antimicrobial agents alongside growth factors, providing dual functionality. For example, silver‑based dressings with embedded PDGF have shown synergistic antibacterial and pro‑healing effects in vitro.
  • Enhanced tissue regeneration: Beyond closure, growth factors improve the quality of healed tissue, with better vascularization and less fibrosis. VEGF‑loaded dressings result in denser capillary networks, while TGF‑β3 can reduce scar width and improve tensile strength.
  • Decreased scarring: Properly timed growth factor delivery can modulate collagen deposition and reduce hypertrophic scar formation. bFGF has been particularly noted for its anti‑scarring properties when applied early in healing.
  • Tailored delivery: Various dressing platforms allow customization of release profiles, growth factor combinations, and mechanical properties. This flexibility enables personalized treatment for different wound types and patient factors.
  • Potential for combination with other therapies: Growth factor dressings can be used alongside negative pressure wound therapy, hyperbaric oxygen, or skin grafts, potentially boosting overall efficacy.

Challenges

  • Stability: Growth factors are proteins that can denature or degrade during manufacturing, storage, and application. Cold chain requirements (typically 2–8°C) increase cost and logistical complexity. Lyophilized formulations and nanoparticle encapsulation are addressing this, but room‑temperature stable products are still rare.
  • Controlled release: Achieving the right concentration over the right timeframe is difficult. Burst release can cause adverse effects (e.g., excessive granulation, pain), while insufficient release reduces efficacy. Many experimental dressings show promising release profiles in vitro but fail to maintain therapeutic levels in the protease‑rich wound environment. Enzyme‑responsive release systems, such as those triggered by collagenase or elastase, may offer a solution.
  • Immune responses: Exogenous growth factors may elicit antibody formation or unwanted inflammation, especially with repeated use. Animal‑derived growth factors carry higher immunogenicity risk; recombinant human factors are safer but can still trigger minor immune reactions in some patients. Long‑term safety data are limited for most dressings.
  • Cost: Recombinant protein production and advanced biomaterials make growth factor dressings significantly more expensive than traditional dressings, limiting widespread adoption. A single collagen‑PDGF dressing can cost $100–$300, compared to $5–$20 for standard foam dressings. Reimbursement policies vary, and many payers require evidence of cost‑effectiveness before covering these products.
  • Regulatory hurdles: Combination products (drug + device) face complex regulatory pathways, delaying market entry. In the U.S., they are regulated by the FDA’s Center for Drug Evaluation and Research (CDER) or Center for Biologics Evaluation and Research (CBER) as opposed to the simpler 510(k) route for devices. This increases development time and costs. In Europe, the Medical Device Regulation (MDR) has further tightened requirements for dressings containing pharmacologically active substances.
  • Limited clinical evidence for many products: While the strongest evidence exists for PDGF (becaplermin) and bFGF, many novel dressing‑based products have only been tested in small studies or animal models. Larger, multicenter trials with standardized wound measurement and long‑term follow‑up are urgently needed to convince clinicians and payers of their value.

Future Perspectives

Combination Therapies

Future dressings will likely integrate growth factors with other therapeutic agents. For example, combining growth factors with antimicrobial peptides or silver nanoparticles can address both healing and infection simultaneously. Incorporating stem cell–derived secretomes or exosomes that contain a cocktail of growth factors and cytokines offers a multi‑pronged approach that may be more robust than single‑factor delivery. Similarly, adding matrix molecules like hyaluronic acid, elastin, or laminin can provide structural support alongside biochemical signals. Researchers are also exploring the use of gene‑activated matrices, where plasmids encoding growth factors are delivered via the dressing to enable sustained endogenous production. Early animal studies of PDGF‑encoding plasmids in collagen scaffolds have shown prolonged healing improvements compared to protein‑loaded dressings.

Personalized Dressings

With advances in diagnostics, it may become possible to tailor growth factor dressings to individual patients. Wound biomarker analysis—using micro‑sampling of wound fluid or non‑invasive imaging—could identify which growth factors are deficient, allowing for precision therapy. For example, a patient with low VEGF and high MMP‑9 might benefit from a VEGF‑loaded dressing combined with a MMP inhibitor. 3D bioprinting technologies enable the creation of patient‑specific dressings with spatially controlled growth factor gradients, matching wound geometry and healing stage. This could be particularly useful for large or geometrically complex wounds, such as burns or pressure ulcers. Point‑of‑care bioprinting, where a handheld device prints a customized dressing directly on the wound, is an emerging concept that could revolutionize treatment.

Smart Dressings

Smart dressings that sense wound conditions (pH, temperature, infection markers) and release growth factors on demand are on the horizon. For example, pH‑responsive hydrogels can release more growth factors in the acidic environment of a stalled wound (pH <6.5) and reduce release as healing progresses (pH 7.0–7.5). Temperature‑sensitive systems (e.g., thermoresponsive polymers like PNIPAM) can release growth factors in response to local fever or cooling due to inflammation. Integration with wireless sensors could provide real‑time feedback to clinicians and patients, allowing dose adjustments or dressing changes. Although still in early prototypes, several groups have demonstrated smart hydrogel patches that change color when infection is present or release antibiotics on demand. Adding growth factor release to such platforms could create truly intelligent wound dressings.

Clinical Translation and Commercialization

Ongoing research focuses on overcoming the stability and manufacturing challenges. Lyophilization, spray‑drying, and encapsulation in protective nanoparticles are being optimized to produce room‑temperature stable dressing formulations. Companies are investing in scalable electrospinning and 3D printing processes to reduce production costs. More robust clinical trials with uniform endpoints—such as time to 100% closure, wound area reduction at 4 weeks, and recurrence rates—are needed to establish guidelines for use. The Wound Healing Foundation and similar organizations are working toward standardizing outcome measures. As the technology matures and economies of scale improve, growth factor dressings may become standard of care for many wound types, especially diabetic ulcers and burns. Partnerships between academic researchers, biotech firms, and large medical device companies will be key to navigating regulatory pathways and securing reimbursement.

Ethical and Equity Considerations

The high cost of growth factor dressings raises concerns about equitable access. In low‑resource settings, where chronic wounds are common due to diabetes, peripheral vascular disease, and trauma, these advanced products may be unaffordable. Efforts to develop low‑cost alternatives—such as dressings using plant‑derived growth factors (e.g., from wheat germ or green algae) or recombinant proteins expressed in yeast—are underway. Additionally, open‑source biomaterials and local manufacturing initiatives could help reduce costs. Clinicians must also weigh the benefits of accelerated healing against the risk of promoting tumors in patients with a history of malignancy, as some growth factors have mitogenic potential. Ongoing pharmacovigilance and careful patient selection will be necessary.

Conclusion

Innovative dressings with growth factors represent a transformative step in wound healing. By delivering bioactive signals directly to the wound bed, these dressings can overcome the molecular deficits that plague chronic wounds and enhance healing in acute injuries. While challenges remain in stability, cost, and regulation, the rapid pace of biomaterials research and clinical validation holds great promise. The convergence of combination therapies, personalized medicine, and smart responsive systems will likely yield even more effective solutions in the coming years. For clinicians, staying informed about emerging products and the evidence behind them will be essential to integrating these tools into practice. Ultimately, growth factor dressings have the potential to improve outcomes for millions of patients worldwide, reducing the burden of chronic wounds on individuals and healthcare systems alike.